[Skip to Content]
[Skip to Content Landing]

September 2019 - April 2015

Decade

Year

Issue

April 2018, Vol 4, No. 4, Pages 435-595

Original Investigation

Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):468-475. doi:10.1001/jamaoncol.2017.5123

This randomized clinical trial compares the effectiveness of platelets in additive solution treated with amotosalen–UV-A vs untreated platelets in plasma or in additive solution in patients with thrombocytopenia and malignant hematologic diseases

Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):476-482. doi:10.1001/jamaoncol.2017.4881

This study of a subcohort of women in the PROCAS study evaluates a panel of 18 single-nucleotide polymorphisms in combination with mammographic density for ability to improve classic breast cancer risk prediction.

Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2018;4(4):483-492. doi:10.1001/jamaoncol.2017.4996

This randomized clinical trial examines whether the previously reported improvement in local progression-free survival by adding regional hyperthermia to neoadjuvant chemotherapy vs chemotherapy alone translates into improved survival in patients with soft tissue sarcoma.

Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2018;4(4):495-504. doi:10.1001/jamaoncol.2017.5082

This secondary analysis of a randomized clinical trial examines the association between therapy with tumor-treating fields plus temozolomide and survival and health-related quality of life in patients with glioblastoma after completion of chemoradiotherapy.

Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):506-513. doi:10.1001/jamaoncol.2017.5179

This randomized clinical trial investigates the benefit of concurrent chemoradiotherapy vs radiotherapy alone in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIB squamous cell carcinoma of the uterine cervix.

Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers

Abstract Full Text
free access has active quiz
JAMA Oncol. 2018;4(4):516-521. doi:10.1001/jamaoncol.2017.4942

This cohort study uses data from the prospective NIH-AARP Diet and Health Study to examine whether associations between duration of contraceptive use and ovarian, endometrial, breast, and colorectal cancer risk are altered by modifiable lifestyle characteristics.

Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):522-528. doi:10.1001/jamaoncol.2017.5236

This systematic review and meta-analysis evaluates the types of primary end points used in phase 2 checkpoint-inhibitor trials and assesses the strength of associations for objective response rate with progression-free and overall survival.

Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):529-536. doi:10.1001/jamaoncol.2017.5314

This phase 2 randomized clinical trial examines the treatment regimen of mFOLFOXIRI plus cetuximab followed by either cetuximab or bevacizumab for patients with RAS and BRAF wild-type metastatic colorectal cancer.

Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study

Abstract Full Text
free access has audio
JAMA Oncol. 2018;4(4):537-544. doi:10.1001/jamaoncol.2017.5440

This cohort study of an ongoing phase 1 trial reports long-term clinical outcomes with atezolizumab therapy for patients with metastatic urothelial carcinoma.

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2018;4(4):545-553. doi:10.1001/jamaoncol.2017.5524

This secondary analysis of a randomized clinical trial evaluates the prognostic value of 6 multigene signatures in women with early estrogen receptor–positive breast cancer who have received 5 years of endocrine therapy.

Comparison of Residual Risk–Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(4):e175092. doi:10.1001/jamaoncol.2017.5092

This modeling study calculates individualized residual risk estimates for patients with early-stage breast cancer and assesses whether defining eligibility based on a minimum residual risk threshold could increase the reliability of clinical trial power calculations.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial

Abstract Full Text
open access online only
JAMA Oncol. 2018;4(4):e175245. doi:10.1001/jamaoncol.2017.5245

This phase 2 randomized clinical trial evaluates the efficacy and safety of Sym004 (a mixture of futuximab and modotuximab) for the treatment of refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy.

Brief Report

HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):554-557. doi:10.1001/jamaoncol.2017.3159

This study compared response to ketoconazole treatment among patients with castration-resistant prostate cancer who had 0, 1, or 2 HSD3B1 variant alleles.

Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):558-562. doi:10.1001/jamaoncol.2017.3164

This cohort study evaluates whether the HSD3B1 (1245C) allele is associated with worse clinical outcomes from androgen-deprivation therapy for biochemical recurrence after radiotherapy.

Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):564-568. doi:10.1001/jamaoncol.2017.3168

This biomarker study examines the efficacy of irinotecan plus panitumumab in patients with advanced colorectal cancer whose tumors had high HER3 messenger RNA expression.

Research Letter

Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):580-581. doi:10.1001/jamaoncol.2017.5544

This database study analyzes trends in infused chemotherapy services performed in the physician office or hospital outpatient setting for commercially insured patients with cancer.

Detecting Chemotherapeutic Skin Adverse Reactions in Social Health Networks Using Deep Learning

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):581-583. doi:10.1001/jamaoncol.2017.5688

This study reports proof-of-principle early detection of chemotherapeutic-associated skin adverse drug reactions from social health networks using a deep learning–based signal generation pipeline to capture how patients describe cutaneous eruptions.

Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):583-585. doi:10.1001/jamaoncol.2018.0024

This cohort study examines recurrence outcomes in patients with fully resected gastroenteropancreatic neuroendocrine tumors.

JAMA Network Insights

Treatment of Advanced Non–Small Cell Lung Cancer in 2018

Abstract Full Text
JAMA Oncol. 2018;4(4):569-570. doi:10.1001/jamaoncol.2017.5190

This Insights characterizes recent advances and describes a framework for the treatment of advanced non–small cell lung cancer.

JAMA Oncology Clinical Evidence Synopsis

Pathogen-Reduced Platelets for the Prevention of Bleeding in People of Any Age

Abstract Full Text
JAMA Oncol. 2018;4(4):571-572. doi:10.1001/jamaoncol.2017.5049

This Clinical Evidence Synopsis summarizes 12 randomized clinical trials to compare whether pathogen-reduced platelets are as effective as standard platelets for the prevention of bleeding in platelet transfusions.

JAMA Oncology Clinical Challenge

Gradually Worsening Pruritic Plaques

Abstract Full Text
has active quiz
JAMA Oncol. 2018;4(4):573-574. doi:10.1001/jamaoncol.2017.3735

A woman in her 20s taking valproic acid and phenytoin for epilepsy presented to the clinic with a 2-month history of gradually worsening pruritic plaques that initially involved the scalp, face, and neck, and later affected the anterior and posterior chest wall, abdomen, upper arms and thighs. What is your diagnosis?

Viewpoint

Navigating Prostate Cancer Screening in the Real World of Primary Care: The Mirage and the Quicksand

Abstract Full Text
JAMA Oncol. 2018;4(4):453-454. doi:10.1001/jamaoncol.2017.5682

This Viewpoint discusses the feasibility of shared decision making among primary care physicians and patients with respect to prostate cancer screening.

Editorial

The Yet Unrealized Promise of Ovarian Cancer Screening

Abstract Full Text
JAMA Oncol. 2018;4(4):456-457. doi:10.1001/jamaoncol.2018.0028

Pathogen Inactivation Strategies to Improve Blood Safety: Let’s Not Throw Pathogen-Reduced Platelets Out With Their Bath Water

Abstract Full Text
JAMA Oncol. 2018;4(4):458-459. doi:10.1001/jamaoncol.2017.4949
Invited Commentary

Technological Advances, Biologic Rationales, and the Associated Success of Chemotherapy With Hyperthermia in Improved Outcomes in Patients With Sarcoma

Abstract Full Text
JAMA Oncol. 2018;4(4):493-494. doi:10.1001/jamaoncol.2017.4941

Tumor-Treating Fields: Answering the Concern About Quality of Life

Abstract Full Text
JAMA Oncol. 2018;4(4):504-505. doi:10.1001/jamaoncol.2017.5062

Concurrent Chemoradiotherapy for Stage IIIB Cervical Cancer—Global Impact Through Power

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):514-515. doi:10.1001/jamaoncol.2017.5078

HSD3B1—A Predictive Biomarker in Advanced Prostate Cancer

Abstract Full Text
JAMA Oncol. 2018;4(4):562-563. doi:10.1001/jamaoncol.2017.3158
JAMA Oncology Patient Page

Hormone Therapy–Related Hot Flashes and Their Management

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):595. doi:10.1001/jamaoncol.2017.4439

This Patient Page provides information on hormone therapy–related hot flashes and their management.

Cancer Care Chronicles

Close Call

Abstract Full Text
JAMA Oncol. 2018;4(4):455. doi:10.1001/jamaoncol.2017.3438
Poetry and Oncology

A Last Draw From the Boneyard

Abstract Full Text
JAMA Oncol. 2018;4(4):591. doi:10.1001/jamaoncol.2017.2915
Comment & Response

Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer

Abstract Full Text
JAMA Oncol. 2018;4(4):585. doi:10.1001/jamaoncol.2017.0487

Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer

Abstract Full Text
JAMA Oncol. 2018;4(4):585-586. doi:10.1001/jamaoncol.2017.0789

Overall Survival vs Disease-Specific Survival

Abstract Full Text
JAMA Oncol. 2018;4(4):586. doi:10.1001/jamaoncol.2016.6786

Overall Survival vs Disease-Specific Survival—Reply

Abstract Full Text
JAMA Oncol. 2018;4(4):586. doi:10.1001/jamaoncol.2017.3865

Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. 2018;4(4):586. doi:10.1001/jamaoncol.2017.3868

Data-Driven Mammography Screening Practices

Abstract Full Text
JAMA Oncol. 2018;4(4):587-588. doi:10.1001/jamaoncol.2017.4069

Ascertainment Bias and Estimating Penetrance

Abstract Full Text
JAMA Oncol. 2018;4(4):587. doi:10.1001/jamaoncol.2017.4573

Data-Driven Mammography Screening Practices—Reply

Abstract Full Text
JAMA Oncol. 2018;4(4):588-589. doi:10.1001/jamaoncol.2017.4072

Human-Machine Collaboration—A New Form of Paternalism?

Abstract Full Text
JAMA Oncol. 2018;4(4):589. doi:10.1001/jamaoncol.2017.1507

Human-Machine Collaboration—A New Form of Paternalism?—Reply

Abstract Full Text
JAMA Oncol. 2018;4(4):589-590. doi:10.1001/jamaoncol.2017.1519
Correction

Incorrect Spelling in Byline

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):590. doi:10.1001/jamaoncol.2018.0640

Errors in Author Affiliations

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):590. doi:10.1001/jamaoncol.2018.1047
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):449. doi:10.1001/jamaoncol.2017.3216
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2018;4(4):435. doi:10.1001/jamaoncol.2017.3215
×